The three are FDA-approved for obesity treatment
Walking 30 minutes most days and adding 2 to 3 sessions of light strength training per week is a reasonable and sustainable approach
We believe HRS9531 has the potential to make a meaningful difference in the lives of people living with obesity. The HRS9531 6 mg results further validate the potential of KAI-9531 to be a transformative therapy for patients living with obesity and overweight, and were excited to start our global Phase 3 program by year-end to evaluate both higher doses and longer treatment durations to unlock the full potential of KAI-9531, said Ron Renaud, President and Chief Executive Officer, Kailera
Its FDA-approved indication is the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy
For those who do not achieve glycemic targets with lifestyle therapy, metformin, and SGLT2i, or who cannot tolerate these agents, whether due to adverse events or because other restrictions apply, other medications are recommended
and by reducing adverse events often the #1 reason that patients stop using GLP-1 drugs Lexarias proprietary DehydraTECH technology could be of vital importance to any of these companies in their pursuit of the next oral GLP-1 drugs, the company explains